This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Studying Gene Expression in Samples From Patients With Rhabdoid Tumors

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: March 10, 2012
Last updated: July 13, 2016
Last verified: July 2016

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and find biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.

Condition Intervention
Brain and Central Nervous System Tumors Kidney Cancer Genetic: DNA analysis Genetic: gene expression analysis Genetic: mutation analysis Genetic: protein expression analysis Other: immunohistochemistry staining method Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Determination of the Frequency of BRG1 and BRM Loss in Rhabdoid Tumors

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Absence or presence BRG1 and BRM expression in rhabdoid tumors
  • Mechanism of suppression of BRG1 and BRM genes

Estimated Enrollment: 25
Study Start Date: March 2012
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
  • To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
  • To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
  • To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
  • To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.

OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.


Ages Eligible for Study:   up to 120 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with rhabdoid tumors


  • Tumor samples from patients diagnosed with rhabdoid tumors
  • Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors
  • Any source of DNA from BRG1-negative tumors (tumors, blood, etc.)
  • Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01553175

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: David Reisman, MD, PhD University of Florida
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01553175     History of Changes
Other Study ID Numbers: AREN12B5
COG-AREN12B5 ( Other Identifier: Children's Oncology Group )
CDR0000728521 ( Other Identifier: Clinical )
NCI-2012-00705 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Study First Received: March 10, 2012
Last Updated: July 13, 2016

Keywords provided by Children's Oncology Group:
childhood atypical teratoid/rhabdoid tumor
rhabdoid tumor of the kidney

Additional relevant MeSH terms:
Kidney Neoplasms
Carcinoma, Renal Cell
Nervous System Neoplasms
Central Nervous System Neoplasms
Rhabdoid Tumor
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Nervous System Diseases
Neoplasms, Complex and Mixed processed this record on September 21, 2017